BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34471053)

  • 21. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
    Devulapally R; Sekar TV; Paulmurugan R
    Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.
    Pawlik A; Słomińska-Wojewódzka M; Herman-Antosiewicz A
    Eur J Nutr; 2016 Apr; 55(3):1165-80. PubMed ID: 26014809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
    Puri S; Juvale K
    Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study.
    Collin LJ; Maliniak ML; Cronin-Fenton DP; Ahern TP; Christensen KB; Ulrichsen SP; Damkier P; Hamilton-Dutoit S; Yacoub R; Christiansen PM; Sørensen HT; Lash TL
    Breast Cancer Res; 2021 Nov; 23(1):103. PubMed ID: 34736510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
    Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
    Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61.
    Bauerschmitz G; Hüchel S; Gallwas J; Gründker C
    Cancer Genomics Proteomics; 2023; 20(6):531-538. PubMed ID: 37889058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
    Fan P; Agboke FA; Cunliffe HE; Ramos P; Jordan VC
    Eur J Cancer; 2014 Nov; 50(16):2866-76. PubMed ID: 25204804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression.
    Sanità P; Capulli M; Teti A; Galatioto GP; Vicentini C; Chiarugi P; Bologna M; Angelucci A
    BMC Cancer; 2014 Mar; 14():154. PubMed ID: 24597899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
    Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
    Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1α.
    Pan Y; Shao D; Zhao Y; Zhang F; Zheng X; Tan Y; He K; Li J; Chen L
    Int J Biol Sci; 2017; 13(6):794-803. PubMed ID: 28656004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
    Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
    Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells.
    Mitani T; Ito Y; Harada N; Nakano Y; Inui H; Ashida H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):122-8. PubMed ID: 24975222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells.
    Steifensand F; Gallwas J; Bauerschmitz G; Gründker C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
    Kim Y; Choi JW; Lee JH; Kim YS
    Hum Pathol; 2015 Jan; 46(1):104-12. PubMed ID: 25456395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
    Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
    Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of human monocarboxylate transporter 4 in skeletal muscle cells: the role of protein kinase C (PKC).
    Narumi K; Kobayashi M; Otake S; Furugen A; Takahashi N; Ogura J; Itagaki S; Hirano T; Yamaguchi H; Iseki K
    Int J Pharm; 2012 May; 428(1-2):25-32. PubMed ID: 22426323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
    Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
    BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of metabolism-related proteins in phyllodes tumors.
    Kwon JE; Jung WH; Koo JS
    Tumour Biol; 2013 Feb; 34(1):115-24. PubMed ID: 22986897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.